New anti-obesity medications (AOMs), including semaglutide and tirzepatide, offer promising options for managing obesity and may be potential treatment options for obstructive sleep apnea
The evidence cited includes the patent's listing in the FDA Orange Book, public statements by Hims's CEO on an August 2024 investor call discussing GLP-1 patent cliffs and acknowledging that semaglutide was not going off patent, and a formal demand letter sent by Novo Nordisk on February 8, 2026, one day before filing
Normally, low blood sugar causes your body to release stress hormones, such as epinephrine
Bone health on aromatase inhibitors Bone density is a particular concern after breast cancer
People with diabetes who use GLP-1 medications primarily for glucose control face different switching considerations than those using these medications solely for weight loss